This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutUnmet NeedCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsMode of ActionVideoCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsPatient ProfilesProfiles of Patients With CAPIdentify ZINFORO® Patient With CAPProfiles of Patients With cSSTIIdentify ZINFORO® Patient With cSSTIDosingRecommended Dosing ScheduleSimple DosingRenal AdjustmentEfficacyCommunity-acquired PneumoniaClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesComplicated Skin & Soft Tissue InfectionsClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesSafetySafetyKey safety featuresLow Incidence of Discontinuation in CAPLow Incidence of Discontinuation in cSSTIClinical & Scientific Data Clinical & Scientific Data Efficacy in the Treatment of CAPClinical Cure Rates Against Relevant PathogensClinical Cure Rates Across Patient SubgroupsDemonstrated Superiority to CeftriaxoneEarly Clinical ResponseReal-world Efficacy in Elderly PatientsConsistent Clinical Cure Rates in cSSTIClinical Cure Rates in Common Causative PathogensClinical Cure Rates in Patients With ComorbiditiesEarly Clinical EfficacyReal-life Efficacy in Clinical PracticeSupport & ResourcesSupport & ResourcesClinical updatesPrescribing InformationVideosWebinarsExplore Materials

Videos cSSTI

In which cSSTI patient types do you think ceftaroline is the most valuable and what are the risk factors for poor prognosis?

 

In this video, Prof. Matthew Dryden describes the treatment of cSSTI, including in which patient types ceftaroline fosamil is most valuable and what are the risk factors associated with its poor prognosis.

PP-ZFO-IND-0289

What is the efficacy of ceftaroline in high-risk patients, such as those with comorbidities, in Phase III cSSTI trials (CANVAS 1 and 2 and COVERS)?

This video describes the efficacy of ceftaroline fosamil in high-risk patients, such as those with comorbidities, in the Phase III cSSTI trials (CANVAS 1, CANVAS 2 and COVERS trials).


PP-ZFO-IND-0292

      

How does the proportion of adverse events in ceftaroline clinical trials compare to real-world experience?

This video provides information on how the proportion of AEs in ceftaroline fosamil clinical trials compare to that in the real-world experience.

Prof. Matthew Dryden and Prof. Tobias Welte describes clinical trials versus the real-world experience.


PP-ZFO-IND-0309

      

How do ceftaroline requirements regarding routine monitoring and dose adjustment depending on body weight etc. compare with other agents, such as vancomycin?

In this video, Prof. Christian Eckmann answers the question, ‘How do ceftaroline fosamil requirements regarding routine monitoring and dose adjustment depend on factors such as body weight compared to other agents such as vancomycin?’


PP-ZFO-IND-0310

      

Considering appropriate therapy in patients with cSSTI

This video provides information on considering the appropriate therapy in patients with cSSTI, which was presented in the ZINFORO® Satellite Symposium at the ECCMID 2018 and filmed post event for educational purposes by Prof. Christian Eckmann.

PP-ZFO-IND-0300

      

ZINFORO® binds with high affinity to PBP 1, 2 and 3 in MSSA and PBP 2a in MRSA

This video describes the MoA of ZINFORO® (ceftaroline fosamil) on the indications CAP and cSSTI.

PP-ZFO-IND-0302

      

ZINFORO® in patients with cellulitis in cheek

This video provides information on ceftaroline fosamil in patients with cellulitis in the cheek: Patient Case Animation – Case 2 (cSSTI).

PP-ZFO-IND-0328

      

ZINFORO® in patients with cSSTI not responding to initial treatment

This video provides information on ceftaroline fosamil in patients with cSSTI not responding to the initial treatment: Patient Case Animation – Case 4 (cSSTI).

PP-ZFO-IND-0303

      

ZINFORO® provides rapid and potent activity against key causative pathogens in CAP and cSSTI

This video provides information on how ZINFORO® delivers a rapid and potent activity against the key causative pathogens in cSSTI.

PP-ZFO-IND-0326

      

For the treatment of cSSTI, in which patient types do you think ceftaroline is the most valuable and where you fit ceftaroline into the current treatment pathway?

In this video, Prof. Matteo Bassetti describes the treatment of cSSTI, including in which patient types ceftaroline fosamil is most
valuable and where ceftaroline fosamil fits into the current treatment pathway.

PP-ZFO-IND-0319

      

Header
Header Header Header
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Content Content Content
Ceftaroline fosamil versus vancomycin plus aztreonam in the treatment of cSSTI

This video provides information about CANVAS 1 and CANVAS 2, an analysis of clinical response at Day 3 in 2 Phase III trials of ceftaroline fosamil versus vancomycin plus aztreonam in the treatment of cSSTIs.

PP-ZFO-IND-0387

      


​​​​​​​

AE, adverse event; CANVAS, CeftAroliNe Versus vAncomycin in Skin and skin structure infections; CAP, community-acquired pneumonia; COVERS, CeftarOline versus Vancomycin and aztrEonam tReating cSSTI; cSSTI, complicated skin and soft tissue infection; ECCMID, European Congress of Clinical Microbiology and Infectious Diseases; MOA, mode of action.


​​​​​Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
​​​​​​​
PP-ZFO-IND-0417 June 2022
Videos
About

Fifth-generation cephalosporin with broad coverage

 Learn more


Efficacy

Proven clinical efficacy in patients with
CAP and cSSTI

 Review efficacy profile


Dosing

Simple dosing with a flexible infusion time

Learn moreLoading


Safety

Safety profile consistent with other cephalosporins

 Review safety profile


Clinical & Scientific Data

​​​​ZINFORO® in the treatment of CAP and cSSTI​​​​​​

 Learn more
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ZFO-IND-0417

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023
Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023